<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24265387</article-id><article-id pub-id-type="pmc">3836147</article-id><article-id pub-id-type="publisher-id">1683</article-id><article-id pub-id-type="doi">10.2337/dc13-1683</article-id><article-categories><subj-group subj-group-type="heading"><subject>Online Letters: Comments and Responses</subject></subj-group></article-categories><title-group><article-title>Response to Comment on: Bosi et al. Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes: The PRISMA Randomized Trial. Diabetes Care 2013;36:2887&#x02013;2894</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bosi</surname><given-names>Emanuele</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Scavini</surname><given-names>Marina</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ceriello</surname><given-names>Antonio</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cucinotta</surname><given-names>Domenico</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tiengo</surname><given-names>Antonio</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marino</surname><given-names>Raffaele</given-names></name><degrees>MD, MBA</degrees><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bonizzoni</surname><given-names>Erminio</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Giorgino</surname><given-names>Francesco</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><collab>on behalf of the PRISMA Study Group</collab></contrib><aff id="aff1"><sup>1</sup>Diabetes Research Institute, San Raffaele Hospital and Scientific Institute, Milan, Italy</aff><aff id="aff2"><sup>2</sup>San Raffaele Vita-Salute University, Milan, Italy</aff><aff id="aff3"><sup>3</sup>Institut d&#x02019;Investigacions Biom&#x000e8;diques August Pi Sunyer and Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadis, Barcelona, Spain</aff><aff id="aff4"><sup>4</sup>Department of Internal Medicine, Policlinico Universitario Gaetano Martino, Messina, Italy</aff><aff id="aff5"><sup>5</sup>Department of Clinical and Experimental Medicine, Division of Metabolic Diseases, University of Padova, Padova, Italy</aff><aff id="aff6"><sup>6</sup>Medical Affairs, Roche Diagnostics, Monza, Italy</aff><aff id="aff7"><sup>7</sup>Department of Occupational Health Clinica del Lavoro L. Devoto, Section of Medical Statistics and Biometry G.A. Maccacaro, School of Medicine, University of Milan, Milan, Italy</aff><aff id="aff8"><sup>8</sup>Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology, and Metabolic Diseases, University of Bari School of Medicine, Bari, Italy</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Emanuele Bosi, <email>bosi.emanuele@hsr.it</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>13</day><month>11</month><year>2013</year></pub-date><volume>36</volume><issue>12</issue><fpage>e218</fpage><lpage>e218</lpage><permissions><copyright-statement>&#x000a9; 2013 by the American Diabetes Association.</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="e218.pdf"/><counts><page-count count="1"/></counts></article-meta></front><body><p content-type="flushleft">We thank Kleefstra et al. (<xref ref-type="bibr" rid="B1">1</xref>) for their interest in our study (<xref ref-type="bibr" rid="B2">2</xref>). However, we disagree with the assertions regarding the clinical relevance of our findings on the use of self-monitoring of blood glucose (SMBG) in noninsulin-treated type 2 diabetes.</p><p>Although the traditional approach to evaluating the efficacy of pharmacological interventions in type 2 diabetes studies is to report between-group differences in HbA<sub>1c</sub> reductions, this approach may not be appropriate for assessing the impact of &#x0201c;behavior-based&#x0201d; interventions such as structured SMBG. In pharmacological studies, a medication is administered and investigators measure its efficacy in lowering glucose by comparing the reduction in HbA<sub>1c</sub> values over time in all patients in the intervention and control group (intent-to-treat [ITT] population). Several researchers, erroneously in our opinion, apply this approach also when evaluating the efficacy of SMBG, looking only at what happens when subjects are asked to perform SMBG, without considering whether patients and/or their clinicians actually do so and interpret and use the data to adjust therapy. In essence, they consider only the <italic>performance</italic> of SMBG as the intervention. Conversely, assessing the proportion of patients who truly complied with the study procedures related to use of structured SMBG (per protocol [PP] population) may provide a more accurate metric for evaluating this type of intervention because it reflects the impact of the complete mode of action (testing and interpreting/using the data) of the intervention (<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>). In fact, in our study the between-group difference in HbA<sub>1c</sub> reduction over 12 months was greater in the PP population (&#x02212;0.21% [95% CI &#x02212;0.331 to &#x02212;0.089], <italic>P</italic> = 0.0007) than in the ITT population (all randomized patients) (&#x02212;0.12% [&#x02212;0.210 to &#x02212;0.024], <italic>P</italic> = 0.013). Similarly, the between-group proportion of patients achieving clinically significant reductions in HbA<sub>1c</sub> at study end (e.g., either &#x0003e;0.3%, &#x0003e;0.4%, or &#x0003e;0.5%) was greater in the PP than ITT population.</p><p>Additionally, when evaluating the magnitude of HbA<sub>1c</sub> reductions, the baseline HbA<sub>1c</sub> values of study subjects must be considered. As has been shown in numerous intervention studies, diabetic patients with low baseline HbA<sub>1c</sub> values generally achieve significantly smaller HbA<sub>1c</sub> reductions compared with subjects with higher baseline values (<xref ref-type="bibr" rid="B5">5</xref>). Because approximately 57.3% (<italic>n</italic> = 587) of our subjects had a baseline HbA<sub>1c</sub> of &#x0003c;7.5% (only 7.6% [<italic>n</italic> = 78] had HbA<sub>1c</sub> values &#x02265;8.5%), we did not expect large HbA<sub>1c</sub> reductions. However, even with these low baseline values, significantly more intervention subjects achieved clinically significant HbA<sub>1c</sub> reductions (&#x0003e;0.3% or &#x0003e;0.5%) than control subjects.</p><p>Given that diabetes is primarily a self-managed disease, future studies may consider using metrics in study design and data analyses that allow assessing the actual impact of behavior-based interventions. Furthermore, as suggested by the results of our study, we need to focus on subgroups of patients with noninsulin-treated type 2 diabetes who may benefit more from structured SMBG (e.g., patients with higher baseline HbA<sub>1c</sub> values) or where structured SMBG may be a safer choice (e.g., patients with lower baseline HbA<sub>1c</sub> values).</p></body><back><ack><title>Acknowledgments</title><p>The PRISMA study was funded by Roche Diagnostics Diabetes Care. E.Bos. served on the PRISMA Study Advisory Board funded by Roche Diagnostics Diabetes Care and serves on advisory boards for Roche and Abbott. M.S., A.C., D.C., A.T., and F.G. served on the PRISMA Study Advisory Board funded by Roche Diagnostics Diabetes Care. R.M. is an employee of Roche Diagnostics Diabetes Care. E.Bon. served as statistical consultant for Roche Diagnostics Diabetes Care. The medical writing assistance of Christopher G. Parkin, MS (Information and Education Development, CGParkin, Inc., Las Vegas, NV) was supported by Roche Diagnostics Diabetes Care. No other potential conflicts of interest relevant to this article were reported.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Kleefstra</surname><given-names>N</given-names></name><name><surname>Logtenberg</surname><given-names>SJJ</given-names></name><name><surname>Bilo</surname><given-names>HJG</given-names></name></person-group> Comment on: Bosi et al. Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial. Diabetes Care 2013;36:2887&#x02013;2894 (Letter). Diabetes Care 2013;36:e217. DOI: 10.2337/dc13-1394</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosi</surname><given-names>E</given-names></name><name><surname>Scavini</surname><given-names>M</given-names></name><name><surname>Ceriello</surname><given-names>A</given-names></name><etal/><collab>PRISMA Study Group</collab></person-group>
<article-title>Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial</article-title>. <source>Diabetes Care</source>
<year>2013</year>;<volume>36</volume>:<fpage>2887</fpage>&#x02013;<lpage>2894</lpage><pub-id pub-id-type="pmid">23735724</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>International Diabetes Federation/SMBG International Working Group</collab></person-group> IDF guideline on self-monitoring of blood glucose in non-insulin treated type 2 diabetes [Internet]. Available from <ext-link ext-link-type="uri" xlink:href="http://www.idf.org/guidelines/self-monitoring">http://www.idf.org/guidelines/self-monitoring</ext-link> Accessed 30 December 2012</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>CG</given-names></name><name><surname>Buskirk</surname><given-names>A</given-names></name><name><surname>Hinnen</surname><given-names>DA</given-names></name><name><surname>Axel-Schweitzer</surname><given-names>M</given-names></name></person-group>
<article-title>Results that matter: structured vs. unstructured self-monitoring of blood glucose in type 2 diabetes</article-title>. <source>Diabetes Res Clin Pract</source>
<year>2012</year>;<volume>97</volume>:<fpage>6</fpage>&#x02013;<lpage>15</lpage><pub-id pub-id-type="pmid">22464874</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloomgarden</surname><given-names>ZT</given-names></name><name><surname>Dodis</surname><given-names>R</given-names></name><name><surname>Viscoli</surname><given-names>CM</given-names></name><name><surname>Holmboe</surname><given-names>ES</given-names></name><name><surname>Inzucchi</surname><given-names>SE</given-names></name></person-group>
<article-title>Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis</article-title>. <source>Diabetes Care</source>
<year>2006</year>;<volume>29</volume>:<fpage>2137</fpage>&#x02013;<lpage>2139</lpage><pub-id pub-id-type="pmid">16936168</pub-id></mixed-citation></ref></ref-list></back></article>